VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX - Free Report) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Benchmark reiterated a "hold" rating on shares of VolitionRx in a research report on Friday, November 22nd. D. Boral Capital reiterated a "buy" rating and issued a $5.00 price objective on shares of VolitionRx in a report on Wednesday, January 8th.

VolitionRx Price Performance

Shares of NYSE:VNRX traded down $0.03 on Wednesday, hitting $0.63. The company's stock had a trading volume of 46,733 shares, compared to its average volume of 101,184. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The company has a market capitalization of $58.39 million, a PE ratio of -1.75 and a beta of 1.20. The company has a 50-day simple moving average of $0.66 and a 200 day simple moving average of $0.66.

Insider Buying and Selling at VolitionRx

In other VolitionRx news, Director Guy Archibald Innes bought 174,764 shares of the firm's stock in a transaction that occurred on Monday, December 9th. The stock was bought at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the acquisition, the director now directly owns 617,085 shares in the company, valued at $351,738.45. The trade was a 39.51 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Cameron John Reynolds purchased 139,811 shares of the business's stock in a transaction that occurred on Monday, December 9th. The stock was bought at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the acquisition, the chief executive officer now owns 2,117,404 shares of the company's stock, valued at $1,206,920.28. This represents a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 358,266 shares of company stock worth $204,212. 12.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC boosted its holdings in shares of VolitionRx Limited (NYSE:VNRX - Free Report) by 78.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,959 shares of the company's stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC's holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. 8.09% of the stock is owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.